Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 901–1,000 of 2,162
Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models
Yan, H. H., Bhagwat, B., Sanden, D., Willingham, A. T., Tan, A., Knapton, A. D., Weaver, J. L., & Howard, K. E. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.03.020 · Cited by 23
Vissers, M. F. J. M., Heuberger, J. A. A. C., & Groeneveld, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041615 · Cited by 26
Tosca, E. M., Bartolucci, R., Magni, P., & Poggesi, I. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1931114 · Cited by 24
“Immunologically-based AEs range from mild and transient to life-threatening reactions as learned from the tragedy occurred during the FIH study of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T-cells [67].”
InfluentialLymphatic Clearance of Immune Cells in Cardiovascular Disease
Ravaud, C., Ved, N., Jackson, D. G., Vieira, J. M., & Riley, P. R. (2021) · Cells · doi:10.3390/cells10102594 · Cited by 30
“However, in a human phase 1 trial, the use of a super-agonist antiCD28 antibody to induce Treg expansion appeared to be highly toxic and caused a cytokine storm [70].”
BackgroundPerpiñán, C., Bertran, L., Terra, X., Aguilar, C., Binetti, J., López-Dupla, M., Rull, A., Reverté, L., Yeregui, E., Gómez-Bertomeu, F., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030391 · Cited by 27
Miyashita, H., Kurzrock, R., Bevins, N., Thangathurai, K., Lee, S., Pabla, S., Nesline, M., Glenn, S. T., Conroy, J. M., DePietro, P., et al. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00359-8 · Cited by 25
“It is thought that CD80, one of the T-cell priming markers, binds to CD28 on active T cells to activate immune-stimulating signals 56 , so the agonist of CD28 was used in a clinical trial, which resulted in severe cytokine storm in healthy participants 57 .”
MethodTechnical pitfalls when collecting, cryopreserving, thawing, and stimulating human T-cells
Browne, D. J., Miller, C., & Doolan, D. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382192 · Cited by 37
A historical perspective of immunotoxicology
Luster, M. I. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.837121 · Cited by 25
“This became evident following the well-publicized adverse event that occurred with an immunomodulatory anti-CD28 super-agonist mAb (TGN-1412) in a clinical trial in the UK (Suntharalingam et al., 2006).”
BackgroundWoo, J. H., Bour, S. H., Dang, T., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0457-x · Cited by 22
“T cell targeted antibodies such as OKT3 could cause cytokine release and T cell activation/proliferation and subsequently cytokine release syndrome or a sudden and rapid release of proinflammatory cytokines as shown in healthy volunteers that participated in a phase I study of the safety of TGN1412, a humanized supera…”
BackgroundTraining Translators for Smart Drug Discovery
Skarke, C., & FitzGerald, G. A. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000890 · Cited by 24
Antibody C Region Influences TGN1412-like Functional Activity In Vitro
Ball, C., Fox, B. J., Hufton, S. E., Sharp, G., Poole, S., Stebbings, R., Eastwood, D., Findlay, L., Parren, P. W. H. I., Thorpe, R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201795 · Cited by 22
Long Peptide Vaccination Can Lead to Lethality through CD4+ T Cell-Mediated Cytokine Storm
Kitamura, H., Sedlik, C., Jacquet, A., Zaragoza, B., Dusséaux, M., Prémel, V., Sastre‐Garau, X., & Lantz, O. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000933 · Cited by 23
Monkey-based Research on Human Disease: The Implications of Genetic Differences
Bailey, J. (2014) · Alternatives to Laboratory Animals · doi:10.1177/026119291404200504 · Cited by 33
Development of Antibody-Based Therapeutics: Translational Considerations
Tabrizi, M. A., Klakamp, S. L., & Bornstein, G. G. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3 · Cited by 26
Jing, W., Gershan, J. A., Holzhauer, S., Weber, J. J., Palen, K. A., McOlash, L., Pulakanti, K., Wesley, E., Rao, S., Johnson, B. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1309 · Cited by 23
Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology
Curran, M., Mairesse, M., Matas‐Céspedes, A., Bareham, B. R., Pellegrini, G., Liaunardy, A., Powell, E., Sargeant, R., Cuomo, E. M., Stebbings, R., et al. (2019) · Toxicologic Pathology · doi:10.1177/0192623319886304 · Cited by 24
“Events were later attributed to a cytokine storm event within the first 4 hours following dosing.(87) The preclinical assessments of this monoclonal antibody, including in vivo nonhuman primate studies, had not indicated signs of proinflammatory effects or toxicities as indicated in the investigator’s brochure(88) and…”
BackgroundThe Role of CD97 in Regulating Adaptive T-Cell Responses
Spendlove, I., & Sutavani, R. V. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-7913-1_12 · Cited by 29
McDium, J. E., Muenzer, J. T., Rachdi, L., Chang, K. C., Davis, C. G., Dunne, W. M., Piwnica-Worms, D. R., Bernal‐Mizrachi, E., & Hotchkiss, R. S. (2007) · The FASEB Journal · doi:10.1096/fj.07-8283com · Cited by 22
T cell immunomodulation—the Holy Grail of therapeutic tolerance
Isaacs, J. D. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.05.001 · Cited by 22
Clinical pharmacology or translational medicine and therapeutics: reinvent or rebrand and expand?
FitzGerald, G. A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100044 · Cited by 22
Kulhánková, K., Rouse, T. M., Nasr, M. E., & Field, E. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043609 · Cited by 23
“known to expand and activate Tregs have risked enhancing conventional T cell contamination ex vivo [6] and conventional T cell activation in vivo [7].”
BackgroundGiri, S., & Bader, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.012 · Cited by 22
Imidazoquinoline-Conjugated Degradable Coacervate Conjugate for Local Cancer Immunotherapy
Li, H., Herck, S. V., Liu, Y., Hao, Y., Ding, X., Nuhn, L., Zhong, Z., Combes, F., Sanders, N. N., Lienenklaus, S., et al. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00485 · Cited by 23
“After inoculation of the tumor cells, the solid tumors were allowed to grow ≥100 mm3, then mice were divided into four groups (six mice per group): (1) demi water (Control); (2) IMDQ (0.”
MethodMansouri, V., Yazdanpanah, N., & Rezaei, N. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1984449 · Cited by 23
Sundaram, D. N. M., Plianwong, S., Remant, K. C., Ostergaard, H. L., & Uludağ, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.030 · Cited by 22
Immunotherapeutic Agents for Intratumoral Immunotherapy
Shyr, C., Liu, L.-C., Chien, H.-S., & Huang, C. (2023) · Vaccines · doi:10.3390/vaccines11111717 · Cited by 25
“For instance, the anti-CD28 monoclonal antibody that directly stimulates T cells, when tested in a phase 1 trial, with a single intravenous dose of the drug caused a severe cytokine storm response in six healthy young male volunteers [84].”
BackgroundPrinciples for the ethical analysis of clinical and translational research
Gelfond, J., Heitman, E., Pollock, B. H., & Klugman, C. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4282 · Cited by 25
“’ The TGN1412 trial is an example of a poorly executed study design [66].”
BackgroundDendritic cell-based cancer immunotherapies
Fujii, S., Takayama, T., Asakura, M., Aki, K., Fujimoto, K., & Shimizu, K. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0025-x · Cited by 24
“The danger of this systemic inflammatory response is highlighted in a phase I study in which six healthy volunteers received a dose of the superagonistic anti-CD28 antibody TGN1412 and experienced a massive systemic release of pro-inflammatory cytokines, leading to multi-system organ failure within 16 h (Suntharalinga…”
BackgroundA Real-time Impedance-Based Screening Assay for Drug-Induced Vascular Leakage
Kustermann, S., Manigold, T., Ploix, C. C., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kft336 · Cited by 21
Asthma translational medicine: Report card
Mullane, K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.038 · Cited by 21
Figura, M., Chilton, L., Liacini, A., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02553.x · Cited by 21
“However, the targeting of cell surface molecules with biologic agents can introduce new complications, including cytokine storm (56).”
BackgroundZhang, J., Song, K., Wang, J., Li, Y., Liu, S., Dai, C., Chen, L., Wang, S., & Qin, Z. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1296996 · Cited by 20
Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles
Potter, T. M., Neun, B. W., Rodriguez, J. C., et al. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7352-1_15 · Cited by 21
Matas‐Céspedes, A., Brown, L., Mahbubani, K. T. A., Bareham, B. R., Higgins, J., Curran, M., de Haan, L., Lapointe, J., Stebbings, R., & Saeb‐Parsy, K. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1202 · Cited by 22
Weathering the Storm: Harnessing the Resolution of Inflammation to Limit COVID-19 Pathogenesis
Silberberg, E., Filep, J. G., & Ariel, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863449 · Cited by 24
“This phenomenon is induced by enhanced innate recognition via elevated production of IL-2, IFN-g, and TNF-a, highlighting that protective immunity can become deleterious when it is dysregulated or when T cells escape many of the cell-extrinsic checkpoints (97, 99).”
BackgroundRunnels, H. A., Weber, G. L., Min, J., Kudlacz, E. M., Zobel, J., Donovan, C. B., Thiede, M. A., Zhang, J., Alpert, R., Salafia, M. A., et al. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0010-0 · Cited by 21
Suzuki, R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.7242 · Cited by 21
T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease
Beier, K. C., Kallinich, T., & Hamelmann, E. H. (2007) · European Respiratory Journal · doi:10.1183/09031936.00094406 · Cited by 21
Ethical flaws in the TeGenero trial
Shamoo, A., & Woeckner, E. (2007) · The American Journal of Bioethics · doi:10.1080/15265160601112204 · Cited by 20
Moore, G. L., Zeng, V. G., Diaz, J. E., Bonzon, C., Avery, K. N., Rashid, R., Qi, J., Nam, D. H., Jacinto, J. M., Dragovich, M. A., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0327 · Cited by 21
“We measured the binding affinity of XmAb808 for CD28 using biolayer interferometry and found that it bound to human CD28 with a K D of 213 nmol/L. XmAb808 also cross-reacts with mouse CD28, a property not observed with TGN1412 (22), suggesting distinct binding epitopes for each antibody.”
InfluentialOn the origin of cell functions encoded in the toponome
SCHUBERT, W. J. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.03.009 · Cited by 20
Abdoli, R., & Najafian, N. (2014) · International Journal of Organ Transplantation Medicine · Cited by 26
Vessillier, S., Fort, M. M., O’Donnell, L. M., Hinton, H. J., Nadwodny, K. L., Piccotti, J. R., Rigsby, P., Staflin, K., Stebbings, R., Mekala, D. J., et al. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100042 · Cited by 22
“During the first-in-human (FIH) Phase I clinical trial of TGN1412/theralizumab, (humanized anti-human CD28 superagonist (SA), IgG4), a mAb therapeutic with presumptive anti-inflammatory properties, six healthy volunteers experienced life-threatening, unanticipated CRS [3,4].”
BackgroundTargeting Solid Tumors Using CD3 Bispecific Antibodies
Crawford, A., & Chiu, D. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0073 · Cited by 25
“Although the life-threatening conditions seen with the CD28 superagonist (TGN1412) raised safety concerns in targeting CD28 (15), antibodies that bind to a different epitope on CD28 and lack superagonist activity are currently being investigated.”
BackgroundInfluentialNeurological adverse effects of chimeric antigen receptor T-cell therapy
Saleki, K., Mohamadi, M. H., Alijanizadeh, P., & Rezaei, N. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2248390 · Cited by 23
“Consequently, CRS was explained following the infusion of several antibody-dependent treatments, comprising anti-thymocyte globulin (ATG) [39], the CD28 superagonist TGN1412 [40], and rituximab [41].”
BackgroundZhang, Y., Wen, X., Ouyang, Y., Hu, Y., Fang, X., Zhang, J., & Yin, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24380 · Cited by 21
“Several antibody-based therapies such as the CD28 superagonist TGN1412 [33], rituximab [34], obinutuzumab [35], alemtuzumab [36], and nivolumab [8], as well as non-protein-based cancer drugs, such as oxaliplatin [37] and lenalidomide [38], have been shown to cause CRS. Massive T cell stimulation…”
BackgroundSurrogate approaches in development of monoclonal antibodies
Bornstein, G. G., Klakamp, S. L., Andrews, L., Boyle, W. J., & Tabrizi, M. A. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.014 · Cited by 21
Multi-Specific Antibodies for Cancer Immunotherapy
Jachimowicz, R. D., Borchmann, S., & Rothe, A. (2014) · BioDrugs · doi:10.1007/s40259-014-0091-4 · Cited by 21
“cells, potential toxic side effects due to an overly strong activation as well as unspecific activation without the presence of tumor cells, such as the cytokine storm syndrome observed in a clinical trial of a CD28 activating monoclonal antibody [18], have to be avoided.”
BackgroundGood and not so good medical ethics
Rhodes, R. (2015) · Journal of Medical Ethics · doi:10.1136/medethics-2014-102312 · Cited by 20
Monitoring Cytokine Profiles During Immunotherapy
Siebert, J., & Walker, E. (2010) · Immunotherapy · doi:10.2217/imt.10.76 · Cited by 21
Koonrungsesomboon, N., Teekachunhatean, S., Hanprasertpong, N., Laothavorn, J., Na‐Bangchang, K., & Karbwang, J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-2000-2 · Cited by 23
A Mathematical Model of Cytokine Dynamics During a Cytokine Storm
Waito, M., Walsh, S. R., Rasiuk, A. S., Bridle, B. W., & Willms, A. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-30379-6_31 · Cited by 20
“These include infectious diseases such as influenza [16], severe acute respiratory syndrome (SARS) [11], bacteria-induced toxic shock syndrome [20] and sepsis [9], as well as multiple sclerosis [13], graftversus-host disease [7] and sometime adverse effects of therapies [22].”
BackgroundUnderstanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation
Miossec, P. (2020) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2020.2062 · Cited by 20
“Probably the best characterization was observed when normal individuals were exposed to a new agonistic anti-CD28 antibody; a very severe syndrome developed in a few hours (8).”
BackgroundCombination antibody‐based cancer immunotherapy
Takeda, K., Okumura, K., & Smyth, M. J. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00529.x · Cited by 22
Cytotoxicity of Pseudomonas Secreted Exotoxins Requires OxyR Expression
Melstrom, K. A., Kozlowski, R., Hassett, D. J., Suzuki, H., Bates, D. M., Gamelli, R. L., & Shankar, R. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.02.046 · Cited by 25
“In addition, novel treatments, like immunotherapy, have failed to produce meaningful treatment alternatives in large clinical trials [3, 4].”
BackgroundAnaphylactic and Anaphylactoid Causes of Angioedema
Greenberger, P. A. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.09.002 · Cited by 20
Franzoni, C., & Stephan, P. E. (2021) · National Bureau of Economic Research · doi:10.3386/w28562 · Cited by 31
“7 were life-threating for healthy patients (Suntharalingam et al. 2006).”
Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
“A phase I clinical trial of the anti-CD28 Ab TGN1412 exemplifies this, as the Ab induced cytokine storms in treated individuals, causing severe damage to the lungs and kidneys, and an immediate need of transfer to the intensive care unit [365].”
Wei, R., Han, X., Li, M., Ji, Y., Zhang, L., Christodoulou, M., Hameed, N. J., Zhang, C., Gao, R., Liu, J., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01091-0 · Cited by 23
“This syndrome is characterized by excessive production of proin fl ammatory cytokines, such as interleukin (IL)-1 α , IL-1 β , IL-6, and tumor necrosis factor (TNF)- α , leading to systemic in fl ammation, organ failure, and potential death [1 – 5].”
BackgroundSelective Costimulation Blockade With Antagonist Anti-CD28 Therapeutics in Transplantation
Vanhove, B., Poirier, N., Soulillou, J., & Blancho, G. (2019) · Transplantation · doi:10.1097/tp.0000000000002740 · Cited by 19
How to kill Treg cells for immunotherapy
Ellis, G. I., & Riley, J. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-00155-8 · Cited by 18
CON: Regulatory T Cells Are Protective in Ischemic Stroke
Kleinschnitz, C., & Wiendl, H. (2013) · Stroke · doi:10.1161/strokeaha.113.001268 · Cited by 21
Kounis, N. G., Koniari, I. C., GREGORIO, C. D., Assimakopoulos, S. F., Velissaris, D., Hung, M., Mplani, V., Saba, L., Brinia, A., Kouni, S. N., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9080959 · Cited by 21
Healthy volunteers in first‐in‐human oncology drug development for small molecules
Heras, B. D. L., Bouyoucef‐Cherchalli, D., Reeve, L., Reichl, A., Mandarino, D., Flach, S. D., Vidal, L., van Brummelen, E. M. J., & Steeghs, N. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15092 · Cited by 22
“In the TGN1412 case, eight HVs who were enrolled in the phase I clinical trial rapidly developed severe cytokine release syndrome and acute respiratory distress requiring intensive supportive care.(16) To mitigate and manage the risk associated with FIH clinical studies and weigh the option to enrol HVs vs patients, i…”
BackgroundBuchwald, P. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.898035 · Cited by 21
Iyer, V. S., Boddul, S. V., Johnsson, A., Raposo, B., Sharma, R. K., Shen, Y., Kasza, Z., Lim, K. W., Chemin, K., Nilsson, G. P., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102857 · Cited by 23
Inflammatory and Autoimmune Reactions in Atherosclerosis and Vaccine Design Informatics
Jan, M., Meng, S., Chen, N. C., Mai, J., Wang, H., & Yang, X. (2010) · BioMed Research International · doi:10.1155/2010/459798 · Cited by 22
“[86] G.”
BackgroundThe use of antibodies in the prophylaxis and treatment of infections
Lachmann, P. J. (2012) · Emerging Microbes & Infections · doi:10.1038/emi.2012.2 · Cited by 19
Langenhorst, D., Gogishvili, T., Ribechini, E., Kneitz, S., McPherson, K., Lutz, M. B., & Hünig, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050080 · Cited by 19
“While the unexpected cytokine release syndrome induced by a human CD28SA [38], now traced back to the stimulation of effector memory CD4 T-cells [39,40], interrupted the development of this strategy in humans, transient polyclonal Treg activation remains an attractive, and broadly applicable approach for the future.”
BackgroundWin, S. J., Kühl, A. A., Sparwasser, T. D., Hünig, T., & Kamradt, T. (2015) · European Journal of Immunology · doi:10.1002/eji.201546104 · Cited by 22
Yang, Z., Wang, H., Salcedo, T. W., Suchard, S. J., Xie, J., Schneeweis, L. A., Fleener, C., Calore, J. D., Shi, R., Zhang, S. X. Y., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227249 · Cited by 19
“This was evident in the TeGenero incident, where TGN1412, a CD28 The work was supported by Bristol-Myers Squibb Research and Development. dx.doi.org/10.1124/jpet.115.227249.”
BackgroundMethodInfluentialRisks and benefits of multiple sclerosis therapies: need for continual assessment?
Kieseier, B. C., Wiendl, H., Hartung, H.-P., Leussink, V. I., & Stüve, O. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32834696dd · Cited by 20
CD28 between tolerance and autoimmunity: the side effects of animal models
Porciello, N., Kunkl, M., & Tuosto, L. (2018) · F1000Research · doi:10.12688/f1000research.14046.1 · Cited by 20
The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease
Kumar, S., Leigh, N. D., & Cao, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03003 · Cited by 23
Integrating Costimulatory Agonists to Optimize Immune-Based Cancer Therapies
Pardee, A. D., Wesa, A. K., & Storkus, W. J. (2009) · Immunotherapy · doi:10.2217/1750743x.1.2.249 · Cited by 20
Trautmann, L., Said, E. A., Halwani, R., Janbazian, L., Chomont, N., Far, M. E., Breton, G., Haddad, E. K., & Sékaly, R. (2007) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3280ebb5c9 · Cited by 20
Systemic lupus erythematosus, regulatory T cells and pregnancy
Varghese, S., Crocker, I. P., Bruce, I. N., & Tower, C. L. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.59 · Cited by 21
Xue, H., Liang, F., Liu, N., Song, X., Yuan, F., Luo, Y. M., Zhao, X., Long, J., Sun, Y., & Xi, Y. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.110 · Cited by 21
Revisiting Immune-Based Therapies for Aggressive Follicular Cell–Derived Thyroid Cancers
French, J. D. (2013) · Thyroid · doi:10.1089/thy.2012.0566 · Cited by 18
Tuberculosis-immune reconstitution inflammatory syndrome in HIV: from pathogenesis to prediction
Narendran, G., Andrade, B. B., & Swaminathan, S. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.892828 · Cited by 20
“Anti-CD28 therapy (TGN1412) could be an alternative, as in HINI treatment of ARDS, but it causes an acute illness [78].”
BackgroundEsposito, P. B., Grosjean, F., Rampino, T., Libetta, C., Gregorini, M., Fasoli, G., Marchi, G., Sileno, G., Montagna, F., & Canton, A. D. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2013.829470 · Cited by 22
“In fact, six healthy volunteers receiving TGN1412, a humanized superagonistic anti-CD28mAb, developed life-threatening systemic inflammatory syndromes attributable to massive cytokine release (the so-called “cytokine-storm”) [97].”
BackgroundPatel, B., Gauvin, R., Absar, S., Gupta, V., Gupta, N., Nahar, K., Khademhosseini, A., & Ahsan, F. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00076.2012 · Cited by 21
Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
Hennessey, A., Lukawska, J. J., Cambridge, G., Isenberg, D. A., & Leandro, M. J. (2019) · BMC Rheumatology · doi:10.1186/s41927-019-0082-7 · Cited by 21
Sugarman, J., & Levine, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69881-4 · Cited by 19
Monoclonal Antibody Therapy for Cancer
Rader, C. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_3 · Cited by 19
T-Cell Costimulatory Blockade in Organ Transplantation
Maltzman, J. S., & Turka, L. A. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015537 · Cited by 20
“Perhaps the biggest barrier to the application of selective anti-CD28 mAbs in human transplant trials is the catastrophic immune activation that occurred in the trial of the superagonist antiCD28 Ab TGN1412 (Suntharalingam et al. 2006).”
BackgroundChallenges and opportunities in targeting the costimulation pathway in solid organ transplantation
Wojciechowski, D., & Vincenti, F. G. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.002 · Cited by 18
9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland
Reichert, J. M., Beck, A., Lugovskoy, A. A., Wurch, T., Coats, S. R., & Brezski, R. J. (2014) · mAbs · doi:10.4161/mabs.27903 · Cited by 20
“For instance, the induction of cytokine storm in the clinic by the anti-CD28 mAb TGN1412 is indicative of the serious consequences and potential unexpected responses to the use of biotherapeutics in humans.(44) Therefore, advances in safety assays during the development of biotherapeutics can potentially accelerate th…”
BackgroundImmune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone
Al-Sukaini, A., Hornicek, F. J., Peacock, Z. S., Kaban, L. B., Ferrone, S., & Schwab, J. H. (2017) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-017-5451-1 · Cited by 18
Ponzano, S., Blake, K. V., Bonelli, M., & Enzmann, H. G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.899 · Cited by 18
Havard, R., & Stephens, D. M. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0482-6 · Cited by 18
Halade, G. V., Kain, V., de la Rosa, X., & Lindsey, M. L. (2022) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00684.2021 · Cited by 21
Zhu, L., Liu, Z., Cui, Q., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07086-7 · Cited by 18
Analysis of Human Biologics With a Mouse Skin Transplant Model in Humanized Mice
Waldron-Lynch, F., Deng, S., Preston‐Hurlburt, P., Henegariu, O., & Herold, K. C. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04178.x · Cited by 18
“A highly publicized example was the adverse effects of anti-CD28 mAb in patients despite the lack of the effects in mice (9).”
BackgroundMcAuley, D. F., O’Kane, C. M., & Griffiths, M. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181f1fcae · Cited by 21
“The limitations of animal models are clearly highlighted by their failure to predict life-threatening complications in humans, as demonstrated by the cytokine storm seen in human volunteers given an anti-CD28 monoclonal antibody (15).”
BackgroundA simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies
Bailey, L. K., Moreno, L., Manigold, T., Krasniqi, S., Kropshofer, H., Hinton, H. J., Singer, T., Suter‐Dick, L., Hansel, T. T., & Mitchell, J. A. (2012) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2012.12.003 · Cited by 18
Taxonomic applicability of inflammatory cytokines in adverse outcome pathway (AOP) development
Angrish, M. M., Pleil, J. D., Stiegel, M. A., Madden, M. C., MOSER, V. C., & Herr, D. W. (2016) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2016.1138923 · Cited by 18
“These differences become obvious in pharmacological studies, for example, as described by Tarrant (2010) where TGN1412 treatment in cynomolgus macaques and anti-CD28 treatment in rats failed to stimulate blood cytokine changes as seen in phase I clinical trials (Muller and Brennan, 2009; Suntharalingam et al., 2006).”
BackgroundPrevention of Graft-Versus-Host Diseases by in Vivo supCD28mAb-Expanded Antigen-Specific nTreg Cells
Kitazawa, Y., Li, X., Liu, Z., Kimura, H., Isaka, Y., Hünig, T., & Takahara, S. (2010) · Cell Transplantation · doi:10.3727/096368910x508870 · Cited by 18
Augmented Passive Immunotherapy with P4 Peptide Improves Phagocyte Activity in Severe Sepsis
Morton, B., Mitsi, E., Pennington, S. H., Reiné, J., Wright, A. D., Parker, R., Welters, I. D., Blakey, J., Rajam, G., Ades, E. W., et al. (2016) · Shock · doi:10.1097/shk.0000000000000715 · Cited by 17
“The risk of immune hyperstimulation and organ injury is of concern for immunostimulatory therapies (27).”
BackgroundImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
Kimbara, S., & Kondo, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i33.7440 · Cited by 18
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.